← Back to Clinical Trials
Recruiting NCT05122962

NCT05122962 Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05122962
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Tetralogy of Fallot
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2021-11-01
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Remote Heart Rhythm Monitoring

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2021-11-01 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in heart structure in patients with congenital heart disease (CHD)

Eligibility Criteria

Inclusion Criteria: * Moderate (or greater) PR based on quantitative Doppler echocardiography. * Repaired TOF * Congenital Heart Disease diagnosis including but not limited to Ebstein's anomaly, coarctation of the aorta (COA), Fontan palliation, transposition of the great arteries, congenitally corrected transposition of the great arteries. Exclusion Criteria: * Pregnant Women * Unable to undergo CMRI

Contact & Investigator

Central Contact

Halley Davison

✉ RSTACHDRESPRG@mayo.edu

📞 507-422-6246

Principal Investigator

Alexander Egbe, MBBS, MPH

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT05122962 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Tetralogy of Fallot. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05122962 currently recruiting?

Yes, NCT05122962 is actively recruiting participants. Contact the research team at RSTACHDRESPRG@mayo.edu for enrollment information.

Where is the NCT05122962 trial being conducted?

This trial is being conducted at Rochester, United States.

Who is sponsoring the NCT05122962 clinical trial?

NCT05122962 is sponsored by Mayo Clinic. The principal investigator is Alexander Egbe, MBBS, MPH at Mayo Clinic. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology